# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K091753   
B. Purpose for Submission: This 510(k) premarket notification describes modifications to the current in vitro diagnostic device, ELVIS® HSV ID/Typing Test System (k971662). The current intended use of the device has not been modified, although the exact wording of the indications for use statement has been edited to add clarity regarding appropriate specimen types. The changes to the device involve replacing the current monoclona antibodies (MAbs) used for the typing of Herpes simplex virus type 1 (HSV-1) with two newly developed HSV-1 specific MAbs. Also, the number of HSV-2 specific MAbs will be increased.   
C. Measurand: Herpes simplex virus type 1 (HSV-1) and Herpes simplex virus type 2 (HSV-2)   
D. Type of Test: Cell culture system for viral identification   
E. Applicant: Diagnostic Hybrids, Inc.   
F. Proprietary and Established Names: ELVIS® HSV ID and $\mathrm { D } ^ { 3 }$ Typing Test System   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>GQL</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3305</td><td rowspan=1 colspan=1>Microbiology (83)</td></tr></table>

# H. Intended Use:

The ELVIS $^ \mathrm { \textregistered }$ HSV ID and $\mathrm { D } ^ { 3 }$ Typing Test System provides Cells, Replacement Medium and Test Reagents for the culture, qualitative identification and typing of herpes simplex virus (HSV) from cutaneous or mucocutaneous specimens as an aid in the diagnosis of HSV type 1 (HSV-1) and HSV type 2 (HSV-2) infections. The performance characteristics of this assay have not been established for antiviral therapy, prenatal monitoring or use with cerebral spinal fluid specimens.

# I. Device Description:

The ELVIS ${ } ^ { \mathfrak { P } } \mathrm { H S V }$ ID and $\mathrm { D } ^ { 3 }$ Typing Test System $\mathrm { D } ^ { 3 }$ ELVIS) is comprised of Cells, Replacement Medium and Test Reagents for the culture, qualitative identification and typing of HSV isolated from cutaneous or mucocutaneous specimens collected from patients with clinical suspicion of HSV infection. ELVIS $\mathrm { \Delta \stackrel { \circ } { \operatorname { H S V } } }$ Cells are genetically engineered Baby Hamster Kidney (BHK) cells, which, when infected with either HSV-1 or HSV-2, are induced to generate and accumulate an endogenous, intracellular bacterial enzyme, $\beta$ -galactosidase. Other viruses within the herpesviridae family (e.g., Varicellazoster) are not capable of inducing the formation of this enzyme. HSV infection of the ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ Cells also results in the formation of HSV-type-specific proteins. The presence of these proteins can be detected microscopically when fluorescent labeled HSV-type-specific antibodies are used.

# J. Substantial Equivalence Information:

Characteristics of the ELVI $\mathrm { \Delta S ^ { \mathbb { R } } H S V }$ ID and $\mathrm { D } ^ { 3 }$ Typing Test System and the cleared ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ ID/Typing Test System are described in the Table below:

<table><tr><td colspan="3" rowspan="1">Subject Device and Predicate Device Characteristics</td></tr><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Subject Device</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The ELVIS®HSV ID and D3 TypingTest System provides Cells,Replacement Medium and TestReagents for the culture, qualitativeidentification and typing of Herpessimplex virus (HSV).</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Format</td><td colspan="1" rowspan="1">Shell vials or Multi-well plates</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Principle</td><td colspan="1" rowspan="1">Genetically engineered Baby HamsterKidney (BHK) cells, which, wheninfected with either HSV-1 or HSV-2,are induced to generate and accumulatean endogenous, intracellular bacterialenzyme, β-galactosidase.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Labeling Method</td><td colspan="1" rowspan="1">Direct Method - Using fluoresceinisothiocyanate (FITC) to label HSV-2Specific monoclonal antibodies, andgoat-anti-mouse IgG antibody</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Subject Device</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">MonoclonalAntibodies(MAbs)</td><td colspan="1" rowspan="1">HSV-1: non-labeled specific to epitopeson the HSV-1 protein UL42 HSV-2:FITC labeled specific for HSV-2glycoproteins C, G, and a recombinantglycoprotein G</td><td colspan="1" rowspan="1">HSV-1: non-labeled specific toHSV-1 viral protein occurring inthe nuclei of infected cells and anHSV-1 glycoprotein CHSV-2: FITC labeled specific for</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">HSV-2 glycoproteins C, and G</td></tr><tr><td colspan="1" rowspan="1">ELVIS HSVSolution 3</td><td colspan="1" rowspan="1">Contains goat-anti-mouse IgG ANDEvans Blue</td><td colspan="1" rowspan="1">Contains goat-anti-mouse IgG(NO Evans Blue)</td></tr><tr><td colspan="1" rowspan="1">ConcentratedPBS solution</td><td colspan="1" rowspan="1">Provided</td><td colspan="1" rowspan="1">Not Provided</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Not Applicable

# L. Test Principle:

Specimens are inoculated onto the ELVIS®HSV Cells. After an overnight incubation period (17- to 24-hours), the inoculated monolayers are fixed using the supplied ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ Solution 1. The cells are then stained with the supplied ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ Solution 2T, which contains the chromogenic substrate for the induced $\beta .$ - galactosidase enzyme and the MAbs for typing isolates as HSV-1 or HSV-2. Those cells infected with HSV develop an indigo-blue precipitate, while non-infected cells remain colorless. Only monolayers containing the blue precipitate are examined for the presence of fluorescent cells. Monolayers containing fluorescent cells are reported as positive for HSV-2. Monolayers containing no fluorescent cells are rinsed and stained with the supplied ELVIS $\mathrm { \Phi _ { H S V } }$ Solution 3. After a brief rinse step, the monolayers are examined for fluorescent cells. Monolayers containing fluorescent cells are reported as positive for HSV-1. Monolayers containing no fluorescent cells after staining with ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ Solution 3 are reported as positive for HSV, but not typeable.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

A study was undertaken to demonstrate the reproducibility of HSV identification and typing results obtained with the ELVIS HSV ID and $\mathrm { D } ^ { 3 }$ Typing Test System.

A. Study Design

Ten panels of frozen virus suspensions were created for each testing site to stain and interpret. The vial number of each panel member was staggered for each scheduled run, such that the end-user did not come to expect a certain result for each vial number after the first run. Each panel was inoculated and stained once according to the ELVIS® HSV ID and $\mathrm { \dot { D } } ^ { 3 }$ Typing Test System instructions for use. Two panels per day were tested on separate plates for 5- days (10 total runs). Testing was completed at each site on non-consecutive days over a 10-day period. Positive and negative control wells were

inoculated and stained according to the instructions for use and the results recorded with each run.

Description of Panel Members:   

<table><tr><td rowspan=1 colspan=1>Panel Member</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=1>HSV-1 low level</td><td rowspan=1 colspan=1>SF029* lab adapted QC strain; 200 TCID50/mL</td></tr><tr><td rowspan=1 colspan=1>HSV-1 high level</td><td rowspan=1 colspan=1>SF029 lab adapted QC strain; 1000 TCID50/mL</td></tr><tr><td rowspan=1 colspan=1>HSV-2 low level</td><td rowspan=1 colspan=1>SF028† lab adapted QC strain; 200 TCID50/mL</td></tr><tr><td rowspan=1 colspan=1>HSV-2 high level</td><td rowspan=1 colspan=1>SF028 lab adapted QC strain; 1000 TCID50/mL</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>EMEM with 10% Fetal Bovine Serum</td></tr></table>

\*Isolate confirmed as HSV-1 by 2 FDA cleared IVD devices †Isolate confirmed as HSV-2 by 2 FDA cleared IVD devices

Panel members were manufactured by diluting high-titered master stocks. The dilutions were made with the same lot of EMEM with $10 \%$ Fetal Bovine Serum used as the negative control. These dilutions were frozen at $- 7 0 \mathrm { { } ^ { \circ } C }$ and sent to the testing labs. The dilution’s titer was confirmed pre- and post freezing and found to fall within the expected infectivity range for the study: low level should exhibit less than $10 \%$ of the cells showing fluorescence; high level should exhibit greater than $10 \%$ but less than $50 \%$ of the cells showing fluorescence.

Reproducibility Results:   

<table><tr><td rowspan=1 colspan=1>PanelMember</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Day 1</td><td rowspan=1 colspan=2>Day 2</td><td rowspan=1 colspan=2>Day 3</td><td rowspan=1 colspan=2>Day 4</td><td rowspan=1 colspan=2>Day 5</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Run 1</td><td rowspan=1 colspan=1>Run 2</td><td rowspan=1 colspan=1>Run 1</td><td rowspan=1 colspan=1>Run 2</td><td rowspan=1 colspan=1>Run 1</td><td rowspan=1 colspan=1>Run 2</td><td rowspan=1 colspan=1>Run 1</td><td rowspan=1 colspan=1>Run 2</td><td rowspan=1 colspan=1>Run 1</td><td rowspan=1 colspan=1>Run 2</td></tr><tr><td rowspan=3 colspan=1>HSV-1 lowlevel</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td></tr><tr><td rowspan=3 colspan=1>HSV-1high level</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1 to2+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td></tr><tr><td rowspan=3 colspan=1>HSV-2 lowlevel</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>1 to2+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td></tr><tr><td rowspan=3 colspan=1>HSV-2high level</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>1+</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>2+</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>2+</td><td rowspan=1 colspan=1>3+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>2+</td></tr><tr><td rowspan=3 colspan=1>Negative</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>NEG</td></tr></table>

Key: $+ / - =$ Less than $10 \%$ of cells showing fluorescence $1 + =$ Between 10 to $30 \%$ of cells showing fluorescence $2 + =$ Between 30 to $50 \%$ of cells showing fluorescence $3 + =$ Between 50 to $7 5 \%$ of cells showing fluorescence $4 + =$ Between 75 to $100 \%$ of cells showing fluorescence

Summary:

The presence of HSV was reported in $100 \%$ (120/120) of the wells in which infected cells were present and the expected type was reported $100 \%$ (60/60) for HSV-1 and $100 \%$ (60/60) for HSV-2. The absence of HSV was reported in $100 \%$ (30/30) of the vials in which no virus was present. Controls performed as expected during each run

$b$ . Linearity/assay reportable range: Not Applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Shelf-life was determined for the device as a complete kit. The shelf-life of the device ELVIS® HSV ID and D3 Typing Test System was targeted at 6 months. Kits were stored at $2 \mathrm { { } ^ { \circ } C }$ to $8 \mathrm { { } ^ { \circ } C }$ and tested at the indicated time intervals. Characteristics monitored were performance, as well as pH, color and clarity. Acceptance criterion was “bright fluorescence” (as opposed to “dim fluorescence” or “no fluorescence”) observed in fixed, stained, infected cells [infected to a level of $^ { 2 + }$ to $4 + ( 3 0 { - } 1 0 0 \% )$ cytopathic effect] using ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ Solution 2T reagent at $1 / 1 6$ dilution. The table below summarizes the real-time stability testing results.

<table><tr><td rowspan=1 colspan=4>Real-Time Stability 2-8°c Storage</td></tr><tr><td rowspan=1 colspan=1>StabilityTimepoint</td><td rowspan=1 colspan=1>Lot #Tested</td><td rowspan=1 colspan=1>DateTested</td><td rowspan=1 colspan=1>Result(Pass/Fail)</td></tr><tr><td rowspan=3 colspan=1>Time Zero</td><td rowspan=1 colspan=1>012909NA</td><td rowspan=1 colspan=1>2/5/2009</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>012909NB</td><td rowspan=1 colspan=1>2/5/2009</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>012909NC</td><td rowspan=1 colspan=1>2/5/2009</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=3 colspan=1>3 Month</td><td rowspan=1 colspan=1>012909NA</td><td rowspan=1 colspan=1>4/30/2009</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>012909NB</td><td rowspan=1 colspan=1>4/30/2009</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>012909NC</td><td rowspan=1 colspan=1>4/30/2009</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=3 colspan=1>6 Month</td><td rowspan=1 colspan=1>012909NA</td><td rowspan=1 colspan=1>7/30/2009</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>012909NB</td><td rowspan=1 colspan=1>7/30/2009</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>012909NC</td><td rowspan=1 colspan=1>7/30/2009</td><td rowspan=1 colspan=1>Pass</td></tr></table>

d. Detection limit:

Detection limit of the subject and predicate devices were determined using the ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ cell culture system. Analytical detection limits for HSV-1 and HSV-2 are reported in the table below as numbers of blue staining cells per cell monolayer. Each master stock $( \mathrm { - 1 e 7 - T C I D } _ { 5 0 }$ per mL) virus preparation underwent a series of ten-fold dilutions, which were subsequently inoculated into a 96-well ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ cell culture plate. The plates were centrifuged at $7 0 0 { \mathrm { ~ x ~ g ~ } }$ for 60 minutes, and then incubated at $3 5 \mathrm { { ^ \circ C } }$ to $3 7 ^ { \circ } \mathrm { C }$ for 17-hours.

Each well was stained with the subject and predicate devices then examined at

200X magnification and the number of blue staining cells counted.   
The table below lists the results for each virus strain tested.

<table><tr><td rowspan=1 colspan=4>Limit of Detection compared between ELVIS Subject (D³ ELVIS) andPredicate (Current ELVIS Kit Formulation) Typing Systems</td></tr><tr><td rowspan=2 colspan=1>Virus strain</td><td rowspan=2 colspan=1>Virus perInoculum</td><td rowspan=1 colspan=2>Blue staining cells/well</td></tr><tr><td rowspan=1 colspan=1>ELVIS Predicate</td><td rowspan=1 colspan=1>ELVIS Subject</td></tr><tr><td rowspan=5 colspan=1>HSV-1 Strain FATCC VR-733</td><td rowspan=1 colspan=1>65-TCID50</td><td rowspan=1 colspan=1>74, 67, 65, 69, 70, 64</td><td rowspan=1 colspan=1>76, 70, 63, 68, 72, 71</td></tr><tr><td rowspan=1 colspan=1>6.5-TCID50</td><td rowspan=1 colspan=1>9, 8, 11, 7, 7, 12</td><td rowspan=1 colspan=1>10, 9, 9, 11, 7, 13</td></tr><tr><td rowspan=1 colspan=1>0.65-TCID50</td><td rowspan=1 colspan=1>1, 2, 1, 1, 3, 3</td><td rowspan=1 colspan=1>3, 2, 4, 3, 1, 1</td></tr><tr><td rowspan=1 colspan=1>0.065-TCID50</td><td rowspan=1 colspan=1>0,0, 3, 1, 1, 0</td><td rowspan=1 colspan=1>0,0, 1, 2,0, 0</td></tr><tr><td rowspan=1 colspan=1>0.0065-TCID50</td><td rowspan=1 colspan=1>0,0,0,0,0, 0</td><td rowspan=1 colspan=1>O,O, O, O, O, 0</td></tr><tr><td rowspan=5 colspan=1>HSV-1 CW0H0062Clinical IsolatePassage 2</td><td rowspan=1 colspan=1>85-TCID50</td><td rowspan=1 colspan=1>70, 79, 75, 72, 80, 67</td><td rowspan=1 colspan=1>82, 77, 72, 65, 76, 85</td></tr><tr><td rowspan=1 colspan=1>8.5-TCID50</td><td rowspan=1 colspan=1>10,7,7,6, 9, 6</td><td rowspan=1 colspan=1>11, 10, 8, 6, 7, 7</td></tr><tr><td rowspan=1 colspan=1>0.85-TCID50</td><td rowspan=1 colspan=1>0, 1, 3, 0, 0, 1, 0</td><td rowspan=1 colspan=1>2,0, 0, 0, 2, 2</td></tr><tr><td rowspan=1 colspan=1>0.085-TCID50</td><td rowspan=1 colspan=1>0, 0, 0, 0, 1, 0</td><td rowspan=1 colspan=1>1,0, 0, 0, 1, 0</td></tr><tr><td rowspan=1 colspan=1>0.0085-TCID50</td><td rowspan=1 colspan=1>0,0,0,0,0,0</td><td rowspan=1 colspan=1>0, 0, 0, 0, 0, 0</td></tr><tr><td rowspan=4 colspan=1>HSV-1 CWOH0085Clinical IsolatePassage 2</td><td rowspan=1 colspan=1>60-TCID50</td><td rowspan=1 colspan=1>39, 47, 52, 41, 42, 48</td><td rowspan=1 colspan=1>46, 48, 37, 42, 47, 50</td></tr><tr><td rowspan=1 colspan=1>6.0-TCID50</td><td rowspan=1 colspan=1>6, 10, 11, 8, 7, 15</td><td rowspan=1 colspan=1>7, 14, 9, 8,11, 7</td></tr><tr><td rowspan=1 colspan=1>0.6-TCID50</td><td rowspan=1 colspan=1>2,0,2,0,0, 1</td><td rowspan=1 colspan=1>1, 1, 0, 0, 0, 1</td></tr><tr><td rowspan=1 colspan=1>0.06-TCID50</td><td rowspan=1 colspan=1>0,0,0,0,0, 0</td><td rowspan=1 colspan=1>0,0,0,0,0, 0</td></tr><tr><td rowspan=5 colspan=1>HSV-2 G StrainATCC VR-734</td><td rowspan=1 colspan=1>100-TCID50</td><td rowspan=1 colspan=1>92, 102, 95, 91, 97,90</td><td rowspan=1 colspan=1>95, 96, 97, 98, 89, 103</td></tr><tr><td rowspan=1 colspan=1>10-TCID50</td><td rowspan=1 colspan=1>12, 11, 17, 9, 9, 10</td><td rowspan=1 colspan=1>12, 12, 7, 16, 13, 12</td></tr><tr><td rowspan=1 colspan=1>1.0-TCID50</td><td rowspan=1 colspan=1>3, 2, 1, 1, 3, 4</td><td rowspan=1 colspan=1>5, 1, 2, 2, 1, 3</td></tr><tr><td rowspan=1 colspan=1>0.1-TCID50</td><td rowspan=1 colspan=1>0,1,0,1, 0, 0</td><td rowspan=1 colspan=1>1, 0, 0, 0, 1, 1</td></tr><tr><td rowspan=1 colspan=1>0.01-TCID50</td><td rowspan=1 colspan=1>0,0,0,0,0,0</td><td rowspan=1 colspan=1>0,0,0,0,0,0</td></tr><tr><td rowspan=5 colspan=1>HSV-2 CWOH0082Clinical IsolatePassage 2</td><td rowspan=1 colspan=1>80-TCID50</td><td rowspan=1 colspan=1>70, 67, 73, 78, 70, 62</td><td rowspan=1 colspan=1>76, 77, 64, 80, 70, 69</td></tr><tr><td rowspan=1 colspan=1>8.0-TCID50</td><td rowspan=1 colspan=1>8,7, 10, 11, 6, 5</td><td rowspan=1 colspan=1>7, 8, 14, 11, 11, 9</td></tr><tr><td rowspan=1 colspan=1>0.8-TCID50</td><td rowspan=1 colspan=1>1, 0, 3, 3, 2, 2, 1</td><td rowspan=1 colspan=1>2, 1, 1, 3, 1, 0</td></tr><tr><td rowspan=1 colspan=1>0.08-TCID50</td><td rowspan=1 colspan=1>0,0, 1,0,0, 0</td><td rowspan=1 colspan=1>0, 1, 0, 0, 0, 0</td></tr><tr><td rowspan=1 colspan=1>0.008-TCID50</td><td rowspan=1 colspan=1>0, 0, 0, 0, 0, 0</td><td rowspan=1 colspan=1>0, 0, 0, 0, 0, 0</td></tr><tr><td rowspan=5 colspan=1>HSV-2 CWOH0091Clinical IsolatePassage 2</td><td rowspan=1 colspan=1>55-TCID50</td><td rowspan=1 colspan=1>53, 61, 55, 62, 67, 65</td><td rowspan=1 colspan=1>70, 62, 55, 57, 53, 59</td></tr><tr><td rowspan=1 colspan=1>5.5-TCID50</td><td rowspan=1 colspan=1>3,7,7,9,2,4</td><td rowspan=1 colspan=1>4,4, 7,8, 10, 3</td></tr><tr><td rowspan=1 colspan=1>0.55-TCID50</td><td rowspan=1 colspan=1>1, 0, 0, 2, 2, 1</td><td rowspan=1 colspan=1>3,1,0,0, 2, 2</td></tr><tr><td rowspan=1 colspan=1>0.055-TCID50</td><td rowspan=1 colspan=1>0,0,0,1,0,0</td><td rowspan=1 colspan=1>1,0,0,0,0,0</td></tr><tr><td rowspan=1 colspan=1>0.0055-TCID50</td><td rowspan=1 colspan=1>0,0,0,0,0,0</td><td rowspan=1 colspan=1>0,0,0,0,0,0</td></tr></table>

In this study, the detection limit for the test is defined as the lowest inoculum level at which positive wells (i.e., containing blue staining cells) are observed, in terms of $\mathrm { T C I D } _ { 5 0 }$ . The results presented in the table above indicate that detection limit for both subject and predicate devices averages between 0.65- and $8 . 5 { \mathrm { - } } \mathrm { T C I D } _ { 5 0 }$ for HSV-1 and 0.1 and $8 . 0 { - } \mathrm { T C I D } _ { 5 0 }$ for HSV-2 depending on the strain.

e. Analytical specificity:

The specificity of the MAbs used in the device was assessed using the organisms listed below. The subject device Solution $2 T$ at 2X concentration was tested in duplicate on the prepared slides. After 1-hour at $3 7 ^ { \circ } \mathrm { C }$ , the slides were rinsed with PBS and the subject device Solution 3 secondary stain was added and incubated at $3 7 ^ { \circ } \mathrm { C }$ for 15 minutes. After rinsing and applying Mounting Fluid, the slides were examined at 400X using a fluorescence microscope.

<table><tr><td colspan="4" rowspan="1">Respiratory Cross-Reactivity Testing</td></tr><tr><td colspan="1" rowspan="1">Organism</td><td colspan="1" rowspan="1">Strain or Type</td><td colspan="1" rowspan="1">ELVIS HSV TypingReagent at 2Xconcentration [Positive(+) or Negative (-) forReactivity]</td><td colspan="1" rowspan="1">Concentrations oftargets (viruses:TCID50 inoculumlevel; bacteria: CFU)</td></tr><tr><td colspan="4" rowspan="1">Viruses</td></tr><tr><td colspan="1" rowspan="11">Adenovirus</td><td colspan="1" rowspan="1">Type 1</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Type 3</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Type 5</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Type 6</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Type 7</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Type 8</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Type 10</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Type 13</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Type 14</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Type 18</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Type 31</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="9">Influenza A</td><td colspan="1" rowspan="1">Aichi (H3N2)</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Mal (H1N1)</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Hong Kong (H3N2)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Denver (H1N1)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Port Chalmers(H3N2)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Victoria (H3N2)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">New Jersey(HSWN1)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">WS (H1N1)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">PR (H1N1)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="7">Influenza B</td><td colspan="1" rowspan="1">Hong Kong</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Maryland</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Mass</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">GL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Taiwan</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">JH-001 Isolate</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Russia</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">RSV</td><td colspan="1" rowspan="1">Long</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="2"></td><td colspan="1" rowspan="1">Wash</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">9320</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 1</td><td colspan="1" rowspan="1">C-35</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 2</td><td colspan="1" rowspan="1">Greer</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 3</td><td colspan="1" rowspan="1">C-243</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 4</td><td colspan="1" rowspan="1">M-25</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 4b</td><td colspan="1" rowspan="1">CH-19503</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1000-TCID50</td></tr><tr><td colspan="1" rowspan="1">CMV</td><td colspan="1" rowspan="1">AD169</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">Control Slide</td></tr><tr><td colspan="1" rowspan="1">Varicella-zoster</td><td colspan="1" rowspan="1">Webster</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Control Slide</td></tr><tr><td colspan="1" rowspan="1">Echovirus 7</td><td colspan="1" rowspan="1">ODH-594684</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">Control Slide</td></tr><tr><td colspan="1" rowspan="1">Coxsackievirus A9</td><td colspan="1" rowspan="1">ODH-36685</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Control Slide</td></tr><tr><td colspan="1" rowspan="1">Coxsackievirus B2</td><td colspan="1" rowspan="1">ODH-185</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Control Slide</td></tr><tr><td colspan="1" rowspan="1">Enterovirus 71</td><td colspan="1" rowspan="1">ODH 02-89</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Control Slide</td></tr><tr><td colspan="2" rowspan="1">Bacteria*</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Acinetobacter calcoaceticus</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3.6x10° CFU</td></tr><tr><td colspan="1" rowspan="1">Bordetella bronchiseptica</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.1x1010 CFU</td></tr><tr><td colspan="1" rowspan="1">Bordetella pertussis</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">4.3x10 CFU</td></tr><tr><td colspan="1" rowspan="1">Chlamydia trachomatis</td><td colspan="1" rowspan="1">LGV-II</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Control Slide</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium diphtheriae</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">5.7x107 CFU</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">7.5x10 CFU</td></tr><tr><td colspan="1" rowspan="1">Haemophilis influenzae typeA</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">4.1x109 CFU</td></tr><tr><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.2x10° CFU</td></tr><tr><td colspan="1" rowspan="1">Moraxella cartarrhalis</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.2x1010 CFU</td></tr><tr><td colspan="1" rowspan="1">Mycoplasma hominis</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3.5x1010 CFU</td></tr><tr><td colspan="1" rowspan="1">Mycoplasma orale</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">6.6x10 CFU</td></tr><tr><td colspan="1" rowspan="1">Mycoplasma pneumoniae</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">7.9x109 CFU</td></tr><tr><td colspan="1" rowspan="1">Mycoplasma salivarium</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">7.7x108 CFU</td></tr><tr><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">3.6x10 CFU</td></tr><tr><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">1.0x108 CFU</td></tr><tr><td colspan="1" rowspan="1">Salmonella enteriditis</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">8.7x10 CFU</td></tr><tr><td colspan="1" rowspan="1">Salmonella typhimurium</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">7.5x10 CFU</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">$+r}$</td><td colspan="1" rowspan="1">6.3x10 CFU</td></tr><tr><td colspan="1" rowspan="1">Streptococcus agalactiae</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">5.5x108 CFU</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pneumoniae</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">6.7x109 CFU</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pyogenes</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">6.9x109 CFU</td></tr><tr><td colspan="4" rowspan="1">Yeast*</td></tr><tr><td colspan="4" rowspan="1">Candida glabrata                                                                                1.6x106 CFU</td></tr></table>

\* Turbidity or a color change to yellow indicates possible bacterial contamination and may render a test result unreliable, due either to a technical contamination during the culture setup or to a contaminated specimen. We recommend the original specimen be filtered and recultured.

† Light background fluorescent staining may occur with specimens contaminated with Staphylococcus aureus strains containing large amounts of protein A. Protein A binds to the Fc portions of the conjugated antibodies. Such binding can be distinguished from viral

antigen binding on the basis of morphology, e.g., S. aureus-bound fluorescence appears as small ( ${ \sim } 1$ micron diameter), bright dots.

f. Assay cut-off: Not Applicable

2. Comparison studies:

Method comparison with predicate device:

Studies were performed at three locations using 735 specimens submitted, April through May, 2009, for HSV culture. The number of specimens cultured at each of the three sites: Study site 1 - 299 specimens; Study site 2 - 136 specimens; and Study site 3 - 300 specimens. The specimens were cultured in duplicate and stained concurrently with both devices. The data generated by each site was similar and has been combined for presentation. Of these 735 specimens, 16 were excluded from the final analysis for the reasons listed in the table below.

<table><tr><td rowspan=1 colspan=2>Combined Study Sites RejectedSpecimens/Samples</td></tr><tr><td rowspan=1 colspan=1>Exclusion criteria  Toxic to cell culture</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Exclusion criteria - Contaminated</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Grand Total</td><td rowspan=1 colspan=1>16</td></tr></table>

The table below shows the age and gender distribution for individuals included in the Study:

<table><tr><td rowspan=1 colspan=4>Combined Study Sites - Age and Gender Distribution (720 Specimens)</td></tr><tr><td rowspan=2 colspan=1>Age Range</td><td rowspan=1 colspan=3>Values are # Positive (based on Subject Device) /Total</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>0 to 1 month</td><td rowspan=1 colspan=1>0/9</td><td rowspan=1 colspan=1>1/9</td><td rowspan=1 colspan=1>1/18</td></tr><tr><td rowspan=1 colspan=1>&gt;1 month to 2 years</td><td rowspan=1 colspan=1>0/1</td><td rowspan=1 colspan=1>0/1</td><td rowspan=1 colspan=1>0/2</td></tr><tr><td rowspan=1 colspan=1>&gt;2 to 12 years</td><td rowspan=1 colspan=1>1/7</td><td rowspan=1 colspan=1>4/7</td><td rowspan=1 colspan=1>5/14</td></tr><tr><td rowspan=1 colspan=1>&gt;12 to 21years</td><td rowspan=1 colspan=1>4/22</td><td rowspan=1 colspan=1>54/110</td><td rowspan=1 colspan=1>58/132</td></tr><tr><td rowspan=1 colspan=1>22 to 30 years</td><td rowspan=1 colspan=1>9/34</td><td rowspan=1 colspan=1>71/146</td><td rowspan=1 colspan=1>80/180</td></tr><tr><td rowspan=1 colspan=1>31 to 40 years</td><td rowspan=1 colspan=1>10/37</td><td rowspan=1 colspan=1>44/121</td><td rowspan=1 colspan=1>54/158</td></tr><tr><td rowspan=1 colspan=1>41 to 50 years</td><td rowspan=1 colspan=1>8/22</td><td rowspan=1 colspan=1>18/64</td><td rowspan=1 colspan=1>26/86</td></tr><tr><td rowspan=1 colspan=1>51 to 60 years</td><td rowspan=1 colspan=1>3/14</td><td rowspan=1 colspan=1>15/50</td><td rowspan=1 colspan=1>18/64</td></tr><tr><td rowspan=1 colspan=1>&gt;60 years</td><td rowspan=1 colspan=1>3/18</td><td rowspan=1 colspan=1>9/47</td><td rowspan=1 colspan=1>12/65</td></tr><tr><td rowspan=1 colspan=1>Unknown age</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>0/0</td></tr><tr><td rowspan=1 colspan=1>Grand Total</td><td rowspan=1 colspan=1>38/165</td><td rowspan=1 colspan=1>216/555</td><td rowspan=1 colspan=1>254/719</td></tr></table>

The table below shows the specimen source distribution for the Study:

<table><tr><td rowspan=1 colspan=17>Combined Study Sites - Specimen Source Distribution (719 Specimens) Values are # Positive(based on Subject Device) / Total</td></tr><tr><td rowspan=1 colspan=1>Soree</td><td rowspan=1 colspan=1>Seemsa</td><td rowspan=1 colspan=1>-/+ ouxu</td><td rowspan=1 colspan=1> Ce</td><td rowspan=1 colspan=1>-/+ sud</td><td rowspan=1 colspan=1>-/+ [u</td><td rowspan=1 colspan=1>-/+ qT</td><td rowspan=1 colspan=1>/ Ctc</td><td rowspan=1 colspan=1>-/+ punoM</td><td rowspan=1 colspan=1>-/+  wnnd</td><td rowspan=1 colspan=1>-/+ B[nΛ</td><td rowspan=1 colspan=1>/ </td><td rowspan=1 colspan=1>-/+ T</td><td rowspan=1 colspan=1>/+ </td><td rowspan=1 colspan=1>-/+ ** 4noW</td><td rowspan=1 colspan=1>-/+ !</td><td rowspan=1 colspan=1>Bst a+</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>254/719</td><td rowspan=1 colspan=1>66/175</td><td rowspan=1 colspan=1>18/50</td><td rowspan=1 colspan=1>14/44</td><td rowspan=1 colspan=1>45/105</td><td rowspan=1 colspan=1>23/47</td><td rowspan=1 colspan=1>18/50</td><td rowspan=1 colspan=1>0/4</td><td rowspan=1 colspan=1>16/40</td><td rowspan=1 colspan=1>23/66</td><td rowspan=1 colspan=1>0/12</td><td rowspan=1 colspan=1>5/14</td><td rowspan=1 colspan=1>4/32</td><td rowspan=1 colspan=1>$37</td><td rowspan=1 colspan=1>13/42</td><td rowspan=1 colspan=1>1/1</td></tr><tr><td rowspan=1 colspan=17>* Perineum: anal, groin, buttock, perianal, tailbone**Mouh: mouh, ip, throat, NP Wash, Tongue± Skin: skin, arm, back, breast, finger, foot, leg, thigh, breast, abdomen, handhee,chin, e l</td></tr></table>

The table below shows the comparison of the Subject device with the Predicate device for the isolation and detection of HSV at Study Sites Combined:

<table><tr><td rowspan=1 colspan=4>Combined Study Sites - Subject Device compared to Predicate Device for theIsolation of HSV</td></tr><tr><td rowspan=1 colspan=1>Specimen (719 specimens)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Predicate Device(Current ELVIS Kit Formulation)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>Subject Device (D³3 ELVIS)</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>463</td></tr><tr><td rowspan=1 colspan=2>Positive Percent Agreement (PPA)</td><td rowspan=1 colspan=1>99.6% (250/251)</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=2>95% CI-PPA</td><td rowspan=1 colspan=1>97.8 - 100%</td></tr><tr><td rowspan=1 colspan=2>Negative Percent Agreement (NPA)</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>98.9% (463/468)</td></tr><tr><td rowspan=1 colspan=2>95% CI-NPA</td><td rowspan=1 colspan=1>97.5 - 99.7%</td></tr></table>

The table below shows the comparison of the Subject device with the Predicate device for the identification of HSV-2 at Study Sites Combined:

<table><tr><td rowspan=1 colspan=4>Combined Study Sites - Subject Device compared to Predicate Device for theTyping of HSV-2</td></tr><tr><td rowspan=1 colspan=1>Specimen (106specimens)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Predicate Device HSV-2(Current ELVIS Kit Formulation)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>Subject Device HSV-2(D3 ELVIS)</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=2>Positive Percent Agreement (PPA)</td><td rowspan=1 colspan=1>99.3% (145/146)</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=2>95% CI-PPA</td><td rowspan=1 colspan=1>96.2 - 100%</td></tr><tr><td rowspan=1 colspan=2>Negative Percent Agreement(NPA)</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>94.2% (98/104)</td></tr><tr><td rowspan=1 colspan=2>95% CI-NPA</td><td rowspan=1 colspan=1>87.9 - 97.9%</td></tr></table>

The table below shows the comparison of the Subject device with the

Predicate device for the identification of HSV-2 at Study Sites Combined:

<table><tr><td rowspan=1 colspan=4>Combined Study Sites - Subject Device compared to Predicate Device for theTyping of HSV-1</td></tr><tr><td rowspan=1 colspan=1>Specimen (36 specimens)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Predicate Device HSV-1(Current ELVIS Kit Formulation)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=2 colspan=1>Subject Device HSV-1(D3 ELVIS)</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=2>Positive Percent Agreement (PPA)</td><td rowspan=1 colspan=1>100% (32/32)</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=2>95% CI-PPA</td><td rowspan=1 colspan=1>96.0 - 100%</td></tr><tr><td rowspan=1 colspan=2>Negative Percent Agreement (NPA)</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>87.5% (7/8)</td></tr><tr><td rowspan=1 colspan=2>95% CI-NPA</td><td rowspan=1 colspan=1>47.3 - 99.7%</td></tr></table>

Shell Vial versus Multi-Well Plate Method Comparison Data for the ELVIS $\textsuperscript { \textregistered }$ HSV ID and $D 3$ Typing System:

Each master stock $( \mathrm { { - 5 e 6 - T C I D } _ { 5 0 } }$ per mL) virus preparation was diluted to an inoculum titer of ${ \sim } 1 0 0 { \cdot } \mathrm { T C I D } _ { 5 0 }$ per mL. Three wells of a 24-well ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ cell culture plate and three shell vials with coverslips were inoculated with $1 { \mathrm { - m L } }$ inoculum per isolate. The cultures were centrifuged at $7 0 0 \mathrm { x g }$ for 60 minutes, and then incubated at $3 5 \mathrm { { ^ \circ C } }$ to $3 7 ^ { \circ } \mathrm { C }$ for 17-hours. Each well was stained with the subject device then examined at 200X magnification and the number of blue staining cells and fluorescent plaques counted. The table below lists the virus along with each well’s counts.

<table><tr><td colspan="5" rowspan="1">Evaluation of the subject ELVIS® HSV ID and D3 Typing System withsshell vial versusmulti-well plates cell cultures</td></tr><tr><td colspan="1" rowspan="2">Virus Type andIsolate Number</td><td colspan="2" rowspan="1">Shell Vial Cultures</td><td colspan="2" rowspan="1">Multi-well Plate Cultures</td></tr><tr><td colspan="1" rowspan="1">Blue Cell Counts</td><td colspan="1" rowspan="1">Fluorescent PlaqueCounts</td><td colspan="1" rowspan="1">Blue Cell Counts</td><td colspan="1" rowspan="1">Fluorescent PlaqueCounts</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0072</td><td colspan="1" rowspan="1">34-29-29</td><td colspan="1" rowspan="1">7-6-9</td><td colspan="1" rowspan="1">25-31-29</td><td colspan="1" rowspan="1">6-8-9</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0062</td><td colspan="1" rowspan="1">53-67-65</td><td colspan="1" rowspan="1">30-29-27</td><td colspan="1" rowspan="1">74-69-68</td><td colspan="1" rowspan="1">23-21-29</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0076</td><td colspan="1" rowspan="1">489-495-501</td><td colspan="1" rowspan="1">214-252-249</td><td colspan="1" rowspan="1">470-436-502</td><td colspan="1" rowspan="1">242-236-252</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0061</td><td colspan="1" rowspan="1">60-63-70</td><td colspan="1" rowspan="1">32-39-40</td><td colspan="1" rowspan="1">67-65-66</td><td colspan="1" rowspan="1">35-36-38</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0092</td><td colspan="1" rowspan="1">587-575-602</td><td colspan="1" rowspan="1">394-387-410</td><td colspan="1" rowspan="1">635-595-599</td><td colspan="1" rowspan="1">375-402-415</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0094</td><td colspan="1" rowspan="1">42-42-46</td><td colspan="1" rowspan="1">27-31-36</td><td colspan="1" rowspan="1">43-46-40</td><td colspan="1" rowspan="1">31-29-35</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0081</td><td colspan="1" rowspan="1">302-325-310</td><td colspan="1" rowspan="1">179-170-164</td><td colspan="1" rowspan="1">300-296-325</td><td colspan="1" rowspan="1">182-167-179</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0017</td><td colspan="1" rowspan="1">76-93-89</td><td colspan="1" rowspan="1">49-48-51</td><td colspan="1" rowspan="1">85-96-92</td><td colspan="1" rowspan="1">54-46-49</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0041</td><td colspan="1" rowspan="1">146-153-155</td><td colspan="1" rowspan="1">71-67-77</td><td colspan="1" rowspan="1">158-164-154</td><td colspan="1" rowspan="1">70-75-81</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0085</td><td colspan="1" rowspan="1">68-72-73</td><td colspan="1" rowspan="1">46-43-49</td><td colspan="1" rowspan="1">71-86-77</td><td colspan="1" rowspan="1">50-47-51</td></tr><tr><td colspan="1" rowspan="1">HSV-1CWOH-0084</td><td colspan="1" rowspan="1">46-65-62</td><td colspan="1" rowspan="1">37-30-27</td><td colspan="1" rowspan="1">55-61-52</td><td colspan="1" rowspan="1">31-34-36</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0099</td><td colspan="1" rowspan="1">70-61-57</td><td colspan="1" rowspan="1">23-30-29</td><td colspan="1" rowspan="1">62-65-64</td><td colspan="1" rowspan="1">37-29-34</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0093</td><td colspan="1" rowspan="1">72-77-69</td><td colspan="1" rowspan="1">35-31-39</td><td colspan="1" rowspan="1">75-68-80</td><td colspan="1" rowspan="1">49-42-38</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0086</td><td colspan="1" rowspan="1">176-182-169</td><td colspan="1" rowspan="1">90-72-81</td><td colspan="1" rowspan="1">185-190-178</td><td colspan="1" rowspan="1">82-71-72</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0070</td><td colspan="1" rowspan="1">117-121-110</td><td colspan="1" rowspan="1">54-59-55</td><td colspan="1" rowspan="1">96-120-110</td><td colspan="1" rowspan="1">59-63-62</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0073</td><td colspan="1" rowspan="1">71-72-81</td><td colspan="1" rowspan="1">46-42-35</td><td colspan="1" rowspan="1">69-81-75</td><td colspan="1" rowspan="1">47-45-41</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0078</td><td colspan="1" rowspan="1">112-120-125</td><td colspan="1" rowspan="1">54-69-63</td><td colspan="1" rowspan="1">125-121-135</td><td colspan="1" rowspan="1">64-65-74</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0034</td><td colspan="1" rowspan="1">127-126-123</td><td colspan="1" rowspan="1">72-64-64</td><td colspan="1" rowspan="1">134-121-112</td><td colspan="1" rowspan="1">69-64-70</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0091</td><td colspan="1" rowspan="1">122-119-117</td><td colspan="1" rowspan="1">69-61-70</td><td colspan="1" rowspan="1">119-120-129</td><td colspan="1" rowspan="1">70-78-64</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0025</td><td colspan="1" rowspan="1">131-114-123</td><td colspan="1" rowspan="1">62-59-69</td><td colspan="1" rowspan="1">121-125-118</td><td colspan="1" rowspan="1">69-65-63</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0024</td><td colspan="1" rowspan="1">86-90-92</td><td colspan="1" rowspan="1">39-42-44</td><td colspan="1" rowspan="1">93-91-88</td><td colspan="1" rowspan="1">47-41-43</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0095</td><td colspan="1" rowspan="1">191-204-207</td><td colspan="1" rowspan="1">101-113-105</td><td colspan="1" rowspan="1">191-205-197</td><td colspan="1" rowspan="1">112-95-110</td></tr><tr><td colspan="1" rowspan="1">HSV-2CWOH-0074</td><td colspan="1" rowspan="1">204-197-187</td><td colspan="1" rowspan="1">137-123-140</td><td colspan="1" rowspan="1">240-243-229</td><td colspan="1" rowspan="1">175-183-167</td></tr></table>

3. Clinical studies: Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range:

Clinical studies were performed at three sites with 735 specimens using a legallymarketed device and the ELVIS ${ } ^ { \mathfrak { B } } \mathrm { H S V }$ ID and $\mathrm { D } ^ { 3 }$ Typing Test System. Sixteen specimens were either toxic or contaminated in cell culture, leaving 719 specimens for analysis.

Specimens used in the studies were obtained from a variety of sources. The table below shows the specimen source distribution at the combined Study Sites:

<table><tr><td rowspan=1 colspan=16>Combined Study Sites Specimen Source Distribution Values are # Positive(based on Subject Device)/ Total</td></tr><tr><td rowspan=1 colspan=1>Seeinsar</td><td rowspan=1 colspan=1>uoumn$\fra }$</td><td rowspan=1 colspan=1>eit+</td><td rowspan=1 colspan=1>-/+ su</td><td rowspan=1 colspan=1>-/+ u</td><td rowspan=1 colspan=1>-/+ 1</td><td rowspan=1 colspan=1>C/ Ct</td><td rowspan=1 colspan=1> emnnd$\frac}$</td><td rowspan=1 colspan=1>-/+ Bλ[Λ</td><td rowspan=1 colspan=1>/</td><td rowspan=1 colspan=1>/+</td><td rowspan=1 colspan=1>** 4now$\frac{ }$</td><td rowspan=1 colspan=1>-/+ uµ</td><td rowspan=1 colspan=1>-/+ uos1</td><td rowspan=1 colspan=1>a-/+</td><td rowspan=1 colspan=1>-/+ punoM</td></tr><tr><td rowspan=1 colspan=1>719</td><td rowspan=1 colspan=1>94/175</td><td rowspan=1 colspan=1>18/50</td><td rowspan=1 colspan=1>14/44</td><td rowspan=1 colspan=1>45/105</td><td rowspan=1 colspan=1>23/47</td><td rowspan=1 colspan=1>18/50</td><td rowspan=1 colspan=1>16/40</td><td rowspan=1 colspan=1>23/66</td><td rowspan=1 colspan=1>0/12</td><td rowspan=1 colspan=1>4/32</td><td rowspan=1 colspan=1>9/37</td><td rowspan=1 colspan=1>13/42</td><td rowspan=1 colspan=1>5/14</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>$\frac {{4 }$</td></tr><tr><td rowspan=1 colspan=16> Genital: specific area of genitalia is unknown* Perineum: anal, buttock, tailbone, groin** Mouth: mouth, lip, throat, tongue, nasopharynxSkskin, breast, leg arm, abdomen, thigh, ankle, back, fnger, hand</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.